These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 17947591)

  • 1. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing.
    Tuthill C
    Ann N Y Acad Sci; 2007 Sep; 1112():351-6. PubMed ID: 17947591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymosin alpha1. SciClone Pharmaceuticals.
    Billich A
    Curr Opin Investig Drugs; 2002 May; 3(5):698-707. PubMed ID: 12090542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis treatment update: new approvals, not much news.
    Learned J
    Notes Undergr; 1998-1999 Winter; (No 38):7-8. PubMed ID: 11366197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of lamivudine and thymosin alpha1 combination therapy on patients with chronic hepatitis B].
    Wu F; Yu H; Huang S
    Zhonghua Gan Zang Bing Za Zhi; 2002 Jun; 10(3):218-9. PubMed ID: 12113684
    [No Abstract]   [Full Text] [Related]  

  • 5. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):885-92. PubMed ID: 16307501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19(12):S73-5. PubMed ID: 15641208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Jan; 75(13):3471-2. PubMed ID: 20349552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. International harmonisation - the need for transparency.
    Hodgkin C
    Int J Risk Saf Med; 1996; 9(3):195-9. PubMed ID: 23510917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of thymosine 1 alpha and Lamivudine combination therapy in chronic hepatitis B patients.
    Dikici B; Bosnak M; Haspolat K
    Indian Pediatr; 2002 Jul; 39(7):701-2. PubMed ID: 12147907
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey.
    Saruc M; Yuceyar H; Kucukmetin N; Demir MA; Kandiloglu AR
    Hepatogastroenterology; 2002; 49(45):798-802. PubMed ID: 12063993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma.
    Rasi G; Pierimarchi P; Sinibaldi Vallebona P; Colella F; Garaci E
    Int Immunopharmacol; 2003 Aug; 3(8):1169-76. PubMed ID: 12860172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistical concepts in the planning and evaluation of drug safety from clinical trials in drug development: issues of international harmonization.
    O'Neill RT
    Stat Med; 1995 May 15-30; 14(9-10):117-27. PubMed ID: 7569506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B.
    Liaw YF
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S73-5. PubMed ID: 15546254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Conference on Harmonisation; S10 Photosafety Evaluation of Pharmaceuticals; guidance for industry; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2015 Jan; 80(17):4282-3. PubMed ID: 25730921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B.
    Saruc M; Ozden N; Turkel N; Ayhan S; Hock LM; Tuzcuoglu I; Yuceyar H
    J Pharm Sci; 2003 Jul; 92(7):1386-95. PubMed ID: 12820143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trial of sequential antiviral therapy for patients with chronic hepatitis B in China].
    Lei CL; Peng XM; Tang XP; Yang Z; Fan HM; Yuan XZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Mar; 18(1):69-72. PubMed ID: 15340532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [B domain mutations in the polymerase gene of hepatitis B virus during combination therapy with thymosin alpha1 and famciclovir in Chinese asymptomatic HBV carriers].
    Hou J; Wang Z; Sun J
    Zhonghua Yi Xue Za Zhi; 2000 Aug; 80(8):574-6. PubMed ID: 11798819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Apr; 74(66):15990-1. PubMed ID: 19507321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
    Abbas Z; Hamid SS; Tabassum S; Jafri W
    J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.